Medical Care, Vol. 45, No. 10, Supplement 2: Comparative Effectiveness and Safety: Emerging Methods (Oct., 2007), pp. S143-S148 (6 pages) Background: In observational research, propensity score ...
Sorafenib is currently the only Food and Drug Administration–approved first-line therapy for patients with advanced hepatocellular carcinoma. There are few data examining how sorafenib starting dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback